Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis

被引:1087
作者
Machtay, Mitchell
Moughan, Jennifer
Trotti, Andrew
Garden, Adam S.
Weber, Randal S.
Cooper, Jay S.
Forastiere, Arlene
Ang, K. Kian
机构
[1] Thomas Jefferson Univ Hosp, Dept Radiat Oncol, Jefferson Med Coll, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ Hosp, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] Headquarters & Stat Ctr, Radiat Therapy Oncol Grp, Philadelphia, PA USA
[4] Amer Coll Radiol, Philadelphia, PA USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[6] MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[7] MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA
[8] Maimonides Hosp, Brooklyn, NY 11219 USA
[9] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
关键词
D O I
10.1200/JCO.2007.14.8841
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT. Methods Patients were analyzed from a subset of three previously reported Radiation Therapy Oncology Group (RTOG) trials of CCRT for locally advanced SCCHN (RTOG 91-11, 97-03, and 99-14). Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube >= 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years. Case-control analysis was performed, with a multivariable logistic regression model that included pretreatment and treatment potential factors. Results A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity. On multivariable analysis, significant variables correlated with the development of severe late toxicity were older age (odds ratio 1.05 per year; P=.001); advanced T stage (odds ratio, 3.07; P=.0036); larynx/hypopharynx primary site (odds ratio, 4.17; P=.0041); and neck dissection after CRT (odds ratio, 2.39; P=.018). Conclusion Severe late toxicity after CCRT is common. Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was associated with an increased risk of these complications.
引用
收藏
页码:3582 / 3589
页数:8
相关论文
共 36 条
[1]
Adelstein DJ, 2000, CANCER, V88, P876, DOI 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19>3.0.CO
[2]
2-Y
[3]
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[4]
ANG KK, 2008, INT J RAD ONCOL BI S, V69
[5]
French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma:: Results at 2 years (FNCLCC-GORTEC) [J].
Bensadoun, RJ ;
Bénézery, K ;
Dassonvelle, O ;
Magné, N ;
Poissonnet, G ;
Ramaioli, A ;
Lemanski, C ;
Bourdin, S ;
Tortochaux, J ;
Peyrade, F ;
Marcy, PY ;
Chamorey, E ;
Vallicioni, J ;
Seng, H ;
Alzieu, C ;
Géry, B ;
Chauvel, P ;
Schneider, M ;
Santini, J ;
Demard, FO ;
Calais, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (04) :983-994
[6]
WHY ACTUARIAL ESTIMATES SHOULD BE USED IN REPORTING LATE NORMAL-TISSUE EFFECTS OF CANCER-TREATMENT ... NOW [J].
BENTZEN, SM ;
VAETH, M ;
PEDERSEN, DE ;
OVERGAARD, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 32 (05) :1531-1534
[7]
Individual patients' data meta-analyses in head and neck cancer [J].
Bourhis, Jean ;
Le Maitre, Aurelie ;
Baujat, Bertrand ;
Audry, Helene ;
Pignon, Jean-Pierre .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (03) :188-194
[8]
Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer [J].
Brizel, DM ;
Albers, ME ;
Fisher, SR ;
Scher, RL ;
Richtsmeier, WJ ;
Hars, V ;
George, SL ;
Huang, AT ;
Prosnitz, LR .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) :1798-1804
[9]
Advances in radiation therapy: Conventional to 3D, to IMRT, to 4D, and beyond [J].
Bucci, MK ;
Bevan, A ;
Roach, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) :117-134
[10]
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German cancer society 95-06 prospective randomized trial [J].
Budach, V ;
Stuschke, M ;
Budach, W ;
Baumann, M ;
Geismar, D ;
Grabenbauer, G ;
Lammert, I ;
Jahnke, K ;
Stueben, G ;
Herrmann, T ;
Bamberg, M ;
Wust, P ;
Hinkelbein, W ;
Wernecke, KD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1125-1135